New scan could match breast cancer patients to best therapy

NCT ID NCT06830382

Recruiting now Diagnosis Sponsor: Renske Altena Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a special PET scan that uses a radioactive tracer to detect HER2 protein on cancer cells. The goal is to see if this scan can better identify which patients with metastatic breast cancer will benefit from a targeted drug called T-DXd. About 70 women with advanced breast cancer will receive the scan and then treatment, and researchers will compare scan results to how well the tumor responds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A radioactive tracer called [68Ga]Ga-ABY-025 used in PET scans
What this could lead to: If successful, this imaging method could help doctors choose the right treatment for each patient, improving outcomes and reducing unnecessary side effects.
What could go wrong: This is an early exploratory study with only 70 participants. The scan may not reliably predict treatment response, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER STAGE IV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER STAGE IV HER2-LOW BREAST CANCER MOLECULAR IMAGING

Contacts and locations

Locations

Karolinska University hospital
RECRUITING

Solna, 17176, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.